Assessing the Impact of COVID-19 Patients Long Distance Transfers Between Intensive Care Units

Covid19 Clinical Trial

— TRANSCOV  

Official title:

TRANSCOV Cohort. An Epidemiological Study Assessing the Impact of Critically Ill COVID-19 Patients Long Distance Transfers Between Intensive Care Units

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04930120
• Other study ID #: 20 CO 015 CZ
• Status: Recruiting
• Start date: March 1, 2021
• Est. completion date: December 31, 2022

Study information

• Verified date: June 2021
• Source: Ecole des Hautes Etudes en Santé Publique
• Contact: Olivier Grimaud, Ph.D., M.D
• Phone: 02 99 02 28 34
• Email: olivier.grimaud[@]ehesp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The TRANSCOV cohort is a multicentre observational retrospective study aiming at assessing the health impact of extra regional transfers of critically ill COVID-19 patients.

Description:

In spring 2020 four regions of France faced a surge of severe Coronavirus (COVID) patients which threatened to overflow local intensive care units (ICU) capacities. As an emergency response, between 03/13/2020 and 04/10/2020, an estimated 661 patients were transferred from overcrowded ICUs to other French regions and neighbouring countries. The study aims at assessing the impact of these inter-ICU transfers on the short and medium term physical and psychological outcomes in this population of severe COVID 19 patients.

All transferred patients between ICUs outside the origin region are invited to take part. For each transfer, up to four control patients will be selected among those admitted in the same ICU during the same period (+/-4 days of transfer date). Clinical data will be extracted from medical records and will include hemodynamic and respiratory parameters, as well as clinical severity scores before, during and after transfer. Data linkage with medico-administrative data will enrich the clinical database and allow follow-up up to one year after initial admission.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3060
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• COVID-19 patients diagnosed biologically or by imaging

• Admission in ICU between 03/13/2020 and 04/10/2020

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Covid19

Intervention

Other:
• Inter ICU long distance patient transfer
Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.

Locations

Country	Name	City	State
France	EHESP	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Ecole des Hautes Etudes en Santé Publique

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival	Status alive or dead	1 year